ThinkstockCatalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) announced positive topline results from its Phase 3 clinical trial of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS. In the study, Firdapse was reported…
Ambit Biosciences has announced that it is entering into a merger with Daiichi Sankyo in a deal worth up to $410 million.
What do you do when an analyst report comes out that maintains a price target position that implies shares can more than a double ahead?
Alimera Sciences traded up big on Monday on news that the company received FDA approval for its diabetic macular edema drug Iluvien.
A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could be of the blockbuster variety.
Coherus Biosciences Inc. filed an S-1 with the Securities and Exchange Commission for an initial public offering.
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
For many of the top biotech companies, orphan drugs have morphed into huge winners and have even generated other streams of revenue.
Credit Suisse's $36 price target on Sarepta Therapeutics effectively calls for close to 75% upside.
DBV Technologies has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering
Exagen Diagnostics Inc. has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering
The Joint Corporation has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
Medivation received an upgrade from Canaccord Genuity, citing the company’s potential drug sales of Xtandi as undervalued.
In the after-hours on Wednesday, Flexion Therapeutics made a hard fall on the news of a clinical hold.
Incyte has serious upside potential, but the inherent risk within it may be too much for some investors to bear.